PHARMACY

Court grants Amylin temporary restraining order to bar Lilly from using same sales team

BY Alaric DeArment

SAN DIEGO — Eli Lilly is temporarily barred from using the same sales team to market two diabetes drugs, under a court order issued Thursday.

The U.S. District Court for the Southern District of California issued a temporary restraining order forbidding Lilly from using the same staff to market the drugs Byetta and Bydureon (exenatide), which it developed and co-markets with Amylin Pharmaceuticals, and the recently approved drug Tradjenta (linagliptin), which it developed and co-markets with Boehringer Ingelheim. Bydureon, a long-acting version of Byetta, still is awaiting Food and Drug Administration approval.

Amylin filed suit against Lilly on May 16, alleging that Tradjenta would directly compete against Byetta and Bydureon and that Lilly had thus violated its contractual agreement with Amylin. While both drugs treat Type 2 diabetes, Lilly responded by pointing out that the two drugs did not compete because Tradjenta is an orally administered drug while Byetta and Bydureon are injectables.

“We are disappointed with the court’s decision to grant a temporary restraining order in this case,” Lilly SVP and general counsel Robert Armitage said. “We have complied with our contractual obligations under our agreements with Amylin in a manner fully consistent with all applicable laws. We believe that Amylin’s allegations against Lilly are entirely without merit, and we expect to prevail in this litigation.”

In the meantime, Lilly said it would comply with the restraining order.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Biogen Idec introduces Women in MS educational initiative

BY Allison Cerra

WESTON, Mass. — Biogen Idec is looking to address the advantages and challenges female clinicians experience in treating patients living with multiple sclerosis through a new educational initiative.

"Women in MS," the drug maker said, will includes a series of local seminars held throughout 2011 that feature female healthcare professionals at the forefront of MS research and treatment, as well as a mentor matching service to enable ongoing participant networking. The inaugural seminar took place Tuesday in Seattle and was broadcast live to venues in Seattle, San Diego, Los Angeles and Phoenix.

"The goal of the ‘Women in MS’ initiative is to identify gender-related communication gaps and unmet resource needs, and [to] provide opportunities for clinicians to begin developing and initiating solutions," said Nancy Richert, senior fellow at Biogen Idec. "As a leader in MS treatment for more than 15 years, we are proud to be partnering with treating clinicians on this unique initiative to help drive excellence in MS care."

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Watson acquires Specifar

BY Alaric DeArment

PARSIPPANY, N.J. — Watson Pharmaceuticals has acquired Greek drug maker Specifar Pharmaceuticals for $562 million, the two companies said Wednesday.

Watson said that through the acquisition, it had gained a leading generic product development company that develops and out-licenses products throughout the world, while also enhancing its commercial presence in Europe.

In addition, Watson said, acquiring Specifar would give it a branded-generic presence in Greece’s pharmaceutical market. Specifar is among the top five companies in the Greek branded-generic market.

“We are very pleased that Specifar has become part of our global organization,” Watson president and CEO Paul Bisaro said. “We look forward to working with the management team to continue Specifar’s growth and to expand the opportunities for success within Watson.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?